LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Gronvall, GK (2011)
Publisher: Emerging Health Threats Journal
Journal: Emerging Health Threats Journal
Languages: English
Types: Article
Subjects:
The 2006 US Pandemic and All-Hazards Preparedness Act gave the Department of Health and Human Services (HHS) new authority to fund the development and procurement of medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats. The legislation builds on the authority the HHS gained in 2004 under Project BioShield, which established a fund to procure medical countermeasures. This article reviews the new HHS authorities and the improvements on BioShield, and it describes some of the challenges HHS will face in exercising the new authorities to fund the development and procurement of medical countermeasures against CBRN threats. (Published: 29 February 2008) Emerging Health Threats Journal 2008, 1:e3. doi: 10.3134/ehtj.08.003
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 United States Congress House. Committee on Government Reform. Project BioShield: contracting for the health and security of the American public: hearing before the Committee on Government Reform, House of Representatives, One Hundred Eighth Congress, first session, 4 April 2003. In: U.S. G.P.O.: Washington, 2003. p iii, 128pp.
    • 2 A bill to amend the Public Health Service Act with respect to public health security and all-hazards preparedness and response, and for other purposes: 'Pandemic and All-Hazards Preparedness Act'. In: Public Law No: 109-417, 2006.
    • 3 Library of Congress. The Newshour with Jim Lehrer. State of the Union address. 28 January 2003. PBS: USA, 2003.
    • 4 An Act to amend the Public Health Service Act to provide protections and countermeasures against chemical, radiological, or nuclear agents that may be used in a terrorist attack against the United States by giving the National Institutes of Health contracting flexibility, infrastructure improvements, and expediting the scientific peer review process, and streamlining the Food and Drug Administration approval process of countermeasures. 'Project BioShield Act of 2004'. In: Public Law 108-276. 108th Congress edn. 2004.
    • 5 Gottron F. Project BioShield: appropriations, acquisitions, and policy implementation issues for Congress. Congressional Research Service, 8 March 2007.
    • 6 Russell PK. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin Infect Dis 2007;45 (Suppl 1): S68-S72.
    • 7 Department of Health and Human Services. Procurement Activities. 5 June 2007; available at http://www.hhs.gov/aspr/ barda/procurement/bioshield.html, accessed 12 June 2007.
    • 8 Small Business Innovation Research program. Available at http:// www.zyn.com/sbir/#top, accessed 8 October 2007.
    • 9 Pharmaceutical Research and Manufacturers Association. Press Release: PhRMA's Statement on Senate Passage of S. 15, 'Project Bioshield Act of 2004', 19 May 2004.
    • 10 Department of Health and Human Services. 'Termination LetterFContract No. HHSO1002005000001C,' Letter to VaxGen Inc., 19 December 2006.
    • 11 US biodefenseFshocking and awful. Nat Biotechnol 2007;25:603.
    • 12 Gronvall GK, Smith BT, Matheny J, Mair M, Chamberlain A, Deitch S, et al. Meeting Report: Biomedical Advanced Research and Development Authority (BARDA) Roundtable. Biosecur Bioterror 2007;5:174-9.
    • 13 Federal Acquisition Regulation (FAR). Available at http://www. arnet.gov/far/, accessed 12 June 2007.
    • 14 DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22: 151-85.
    • 15 Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25:420-8.
    • 16 Committee on Methodological Improvements to the Department of Homeland Security's Biological Agent Risk Analysis, Board on Mathematical Sciences and Their Applications, Division on Engineering and Physical Sciences. Interim Report on Methodological Improvements to the Department of Homeland Security's Biological Agent Risk Analysis 2007. The National Academies Press, National Academy of Sciences. 500 Fifth St. N.W., Washington, D.C. 20001.
    • 17 Gilfillan L, Smith BT, Inglesby TV, Kodukula K, Schuler A, Lister M, et al. Taking the measure of countermeasures: leaders' views on the nation's capacity to develop biodefense countermeasures. Biosecur Bioterror 2004;2:320-7.
    • 18 Relman DA. BioterrorismFpreparing to fight the next war. N Engl J Med 2006;354:113-15.
    • 19 Smith BT, Inglesby TV, O'Toole T. Biodefense R&D: anticipating future threats, establishing a strategic environment. Biosecur Bioterror 2003;1:193-202.
    • 20 The White House. Homeland Security Presidential Directive/ HSPD-18: Medical Countermeasures against Weapons of Mass Destruction, 31 January 2007.
    • 21 Gerald Parker, Principal Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness and Response, Office of Public Health Emergency Medical Countermeasures, US Department of Health and Human Services. HHS public health emergency medical countermeasures enterprise implementation plan for chemical, biological, radiological, and nuclear threats, 2007.
    • 22 US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response. HHS Public Health Emergency Medical Countermeasures Enterprise Strategy for Chemical, Biological, Radiological and Nuclear Threats. In: Federal Register, 2006, pp13109-14.
    • 23 Gronvall GK, Matheny J, Smith BT, Mair M, Chamberlain AT, Deitch S, et al. Flexible defenses roundtable meeting: promoting the strategic innovation of medical countermeasures. Biosecur Bioterror 2007;5:271-7.
    • 24 Department of Health and Human Services. HHS Buys Next Generation Smallpox Vaccine. Washington, DC, 4 June 2007.
    • 25 Bavarian Nordic. Stock Exchange Announcement no. 23-07: U.S. Department of Health and Human Services awards an exclusive contract to Bavarian Nordic for the delivery of 20 million doses of IMVAMUNEs. Financial guidance for 2007 is raised with DKK 300 million. 4 June 2007.
    • 26 Elusys Therapeutics Inc. Press Release: NIAID/BARDA awards Elusys a $12 million contract to further develop Anthim, the company's anthrax therapeutic, 2007.
    • 27 PharmAthene, Medarex awarded NIH contract to develop Valortim. Pharmaceut Bus Rev 2007.
    • 28 Emergent BioSolutions. Press release: Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services, 2007.
    • 29 Emergent BioSolutions. Press release: Emergent BioSolutions receives Development Contract from NIAID/BARDA to Fund Continued Development of Anthrax Therapeutic, 2007.
    • 30 Office of the Assistant Secretary for Preparedness and Response, UDoHaHS. HHS Public Health Emergency Medical Countermeasures Enterprise Strategy for Chemical, Biological, Radiological, and Nuclear Threats. In: Federal Register, 2007.
    • 31 US Department of Health and Human Services. HHS Public Health Emergency Medical Countermeasures (PHEMC) Enterprise Stakeholders Workshop, 31 July-2 August 2007. Washington, DC.
    • 32 Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article

Collected from